Siewert Type 1 GEJ Cancer clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
open to eligible people ages 18 years and up
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
at UCLA
Our lead scientists for Siewert Type 1 GEJ Cancer research studies include Rosen Lee.
Last updated: